Cannara Biotech to release fiscal 2025 results Nov. 24

Mr. Zohar Krivorot reports CANNARA BIOTECH INC. TO ANNOUNCE FISCAL Q4 2025 AND FISCAL YEAR 2025 FINANCIAL RESULTS ON NOVEMBER 24, 2025 AND PROVIDES BOARD UPDATE Cannara Biotech Inc. will release its financial results for the fiscal fourth quarter and fiscal year ended Aug. 31, 2025, on Monday, Nov. 24, 2025, at 7 a.m. ET. Cannara Biotech chief executive officer Zohar Krivorot and chief financial officer Nicholas Sosiak will host an earnings webcast on Monday, Nov. 24, 2025, at 11 a.m. ET., consisting of prepared remarks followed by a question-and-answer session. Participants can register for the earnings webcast by visiting the company event section on the company's website. For interested individuals unable to join, the event will be archived on the company's website. Investors are encouraged to submit questions in advance to [email protected]. While live questions will be accepted during the session, priority will be given to those submitted by e-mail. Board update Cannara would also like to announce with great sadness the passing of Jack M. Kay, a long-serving and highly respected member of the board of directors. Mr. Kay, who joined the board in 2019, contributed more than five decades of leadership experience in pharmaceutical and sales executive management to the corporation. Mr. Kay spent 35 years at Apotex Inc., where he held several senior executive positions, including chief executive officer, chief operating officer, president and vice-chairman. He also served in key leadership roles across the pharmaceutical and biotechnology sectors, including chairman of Helix Biopharma Corp. and Cangene Corp. and director of Barr Pharmaceuticals Inc. In addition to his industry contributions, Mr. Kay was a dedicated community leader, notably serving as chairman of the Humber River Regional Hospital (Toronto) and an executive member of several health care and industry organizations. The corporation extends its deepest condolences to Mr. Kay's family and expresses its sincere gratitude for his years of service and meaningful contributions to Cannara. About Cannara Biotech Inc. Cannara is a vertically integrated producer of premium-grade cannabis products at disruptive prices for the Canadian market. Cannara owns two megafacilities based in Quebec spanning over 1.65 million square feet, providing the company with 100,000 kilograms of potential annualized cultivation output. Leveraging Quebec's low electricity costs, Cannara's facilities produce premium-grade cannabis products at an affordable price.